Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389881 | 1.00 | PIK3CA (0.43) | PIK3CAOPRD1KCNH2HRH3SMN1; SMN2 | |
| SCHEMBL390338 | 0.84 | HRH3 (0.56) | PIK3CAOPRD1KCNH2HRH3SMN1; SMN2 | |
| SCHEMBL14340961 | 0.84 | MAPT (0.49) | PIK3CAOPRD1KCNH2HRH3SMN1; SMN2 | |
| SCHEMBL390540 | 0.82 | OPRD1 (0.57) | PIK3CAOPRD1KCNH2HRH3SMN1; SMN2 | |
| SCHEMBL391614 | 0.82 | KDM4E (0.41) | PIK3CAHRH3SMN1; SMN2HPGDSMO | |
| SCHEMBL391613 | 0.82 | KDM4E (0.41) | PIK3CAHRH3SMN1; SMN2HPGDSMO | |
| SCHEMBL390651 | 0.81 | NOS1 (0.49) | PIK3CAOPRD1KCNH2SMN1; SMN2HPGD | |
| SCHEMBL390619 | 0.79 | HRH3 (0.56) | PIK3CAOPRD1KCNH2HRH3SMN1; SMN2 | |
| SCHEMBL390340 | 0.79 | HRH3 (0.54) | OPRD1KCNH2HRH3SMN1; SMN2HPGD | |
| SCHEMBL10167993 | 0.78 | HPGD (0.42) | PIK3CAOPRD1KCNH2HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1870401-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | GRIN1, GRM1, GRIN2C | PIK3CA 3823/4885OPRD1 37/4885KCNH2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.